Insider · CIK 0001654909
Jake Bauer
director
Files at ELVN (Enliven Therapeutics, Inc.), IMVT (Immunovant, Inc.), BBOT (BridgeBio Oncology Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | ELVN Enliven Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +17,126 | $0.00 | $0 | 17,126 | Feb 17, 2026 |
| Aug 26, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +138,193 | $0.00 | $0 | 138,193 | Aug 28, 2025 |
| May 1, 2025 | IMVT Immunovant, Inc. | AGrant or award Common Stock | +25,016 | $0.00 | $0 | 25,016 | May 5, 2025 |
| May 1, 2025 | IMVT Immunovant, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,234 | $0.00 | $0 | 35,234 | May 5, 2025 |
| Feb 6, 2025 | ELVN Enliven Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,491 | $0.00 | $0 | 20,491 | Feb 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.